Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model


Autoria(s): CARNEIRO-LOBO, T. C.; KONIG, S.; MACHADO, D. E.; NASCIUTTI, L. E.; FORNI, M. F.; FRANCISCHETTI, I. M. B.; SOGAYAR, M. C.; MONTEIRO, R. Q.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Background: The expression levels of the clotting initiator protein Tissue Factor (TF) correlate with vessel density and the histological malignancy grade of glioma patients. Increased procoagulant tonus in high grade tumors (glioblastomas) also indicates a potential role for TF in progression of this disease, and suggests that anticoagulants could be used as adjuvants for its treatment. Objectives: We hypothesized that blocking of TF activity with the tick anticoagulant Ixolaris might interfere with glioblastoma progression. Methods and results: TF was identified in U87-MG cells by flow-cytometric and functional assays (extrinsic tenase). In addition, flow-cytometric analysis demonstrated the exposure of phosphatidylserine in the surface of U87-MG cells, which supported the assembly of intrinsic tenase (FIXa/FVIIIa/FX) and prothrombinase (FVa/FXa/prothrombin) complexes, accounting for the production of FXa and thrombin, respectively. Ixolaris effectively blocked the in vitro TF-dependent procoagulant activity of the U87-MG human glioblastoma cell line and attenuated multimolecular coagulation complexes assembly. Notably, Ixolaris inhibited the in vivo tumorigenic potential of U87-MG cells in nude mice, without observable bleeding. This inhibitory effect of Ixolaris on tumor growth was associated with downregulation of VEGF and reduced tumor vascularization. Conclusion: Our results suggest that Ixolaris might be a promising agent for anti-tumor therapy in humans.

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ)

Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho (FAPERJ)

Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Financiadora de Estudos e Projetos (FINEP)

Financiadora de Estudos e Projetos (FINEP)

Identificador

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, v.7, n.11, p.1855-1864, 2009

1538-7933

http://producao.usp.br/handle/BDPI/31008

10.1111/j.1538-7836.2009.03553.x

http://dx.doi.org/10.1111/j.1538-7836.2009.03553.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL PUBLISHING, INC

Relação

Journal of Thrombosis and Haemostasis

Direitos

restrictedAccess

Copyright WILEY-BLACKWELL PUBLISHING, INC

Palavras-Chave #angiogenesis #anticoagulant therapy #glioblastoma #Ixolaris #primary tumor growth #tissue factor #FACTOR PATHWAY INHIBITOR #HEPARIN-BINDING EXOSITE #FACTOR EXPRESSION #BLOOD-COAGULATION #FACTOR-XA #MOLECULAR-MECHANISMS #COLORECTAL-CANCER #PANCREATIC-CANCER #POTENT INHIBITOR #HUMAN GLIOMAS #Hematology #Peripheral Vascular Disease
Tipo

article

original article

publishedVersion